DATA GRAPHICS | Data Byte
More preclinical companies are going public via reverse merger
Preclinical biotechs are a growing share of the private companies seeking a listing via reverse merger
October 27, 2022 9:54 PM UTC
Preclinical companies are not only increasingly accessing the public markets via IPO, they’re also becoming a larger fraction of the companies that go public each year through reverse mergers and SPAC deals.
The number of preclinical IPOs has been on the rise in the past five years, and so far, the companies’ shares have performed about as well as their more advanced peers. ...
BCIQ Company Profiles